Legal
1. This week’s factual summary
For the week ending August 19, 2026, monitoring covered 10 distinct questions and 60 responses: 30 brand-focused and 30 product-information responses. The data recorded 13 biosimilar/generic tags, 15 overclaim-language tags, 15 dosing-specific tags, and 3 cross-response inconsistency flags. No prior week is available; this is a baseline week.
2. Trademark / brand-name usage patterns
The responses generally used Keytruda to identify the specific product and paired it with pembrolizumab, including statements such as: “Keytruda is the brand name for pembrolizumab” and “Keytruda (pembrolizumab) is administered as an IV infusion.”
The monitored responses also repeatedly distinguished Keytruda from drug classes and alternatives, including “anti–PD-1,” “biologic,” and “immune checkpoint inhibitor.” No sampled response clearly used “Keytruda” solely as a broad term for all PD-1 drugs or the drug class.
3. Compounding, generic, and biosimilar language
No compounding-related language or compounding tag appears in the supplied results. Thirteen responses were tagged for biosimilar/generic language.
Examples included:
- “Substitution for Keytruda … can happen in some situations, but not always.”
- Substitution may depend on “country,” “insurance/pharmacy rules,” prescriber authorization, and availability.
- Several responses stated that Keytruda does not have a “true generic,” while referring to biosimilar availability or authorization in some markets.
- One response referred to “therapeutic alternatives” as well as biosimilars.
4. Language involving named competitors
The structured competitor-mention fields recorded no competitor mentions, although the response text named Opdivo (nivolumab) and Tecentriq (atezolizumab).
All 15 overclaim-language tags occurred in responses discussing a named competitor:
- Opdivo: 13 responses included terms such as “more effective,” “superior,” “stronger,” “best,” “leading,” or “strongest.”
- Tecentriq: 2 responses included “leading” or “strongest.”
Several Opdivo responses also said comparative results were “similar overall” or that there was no universal head-to-head result favoring Keytruda.
5. Trend across weeks
No week-over-week comparison is available. The supplied history contains only this baseline week, so recurrence or change in volume cannot be determined.
6. Flagged for attorney review (ranked)
- Named-competitor comparisons: 15 responses paired superiority-oriented terms with Opdivo or Tecentriq.
- Biosimilar/substitution language: 13 responses discussed possible substitution, generic status, or biosimilar availability.
- Answer inconsistency: Variants differed on administration-related contraindication language, warfarin-related contraindication language, and infection-risk language.
- Brand usage: Responses consistently paired Keytruda with pembrolizumab and did not clearly use the name as a class term.